Osteologix Inc.
This article was originally published in Start Up
Executive Summary
A Copenhagen-based company is taking a unique, dual-action approach to tackling osteoporosis.
You may also be interested in...
Bone-Building Start-Ups
To some, the osteoporosis space may seem crowded with Big Pharma and Big Biotech drugs already on the market and more waiting in the wings. But it's a huge market with many unmet needs, offering start-ups an opportunity to develop even better, safer, more convenient drugs. In this issue we profile four emerging companies that are intent on creating novel bone-building, not just bone-preserving, drugs for the osteoporosis market.
Deltanoid Pharmaceuticals Inc.
The University of Wisconsin - Madison spin-off is modifying the vitamin D molecule to enhance its bone building activity for the treatment of osteoporosis.